Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CLNH5
- Development stage
- Preclinical
- Lead developer
- Nascent Biotech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
CLNH5 is a human monoclonal antibody currently in development by Nascent Biotech for the treatment of cancer. It is part of the company's pipeline of fully human antibodies, which are designed to target malignant cells while potentially reducing the immunogenic responses often associated with non-human or chimeric antibodies. While Nascent Biotech's lead clinical candidate, Pritumumab, targets ecto-domain vimentin, the specific biological target and detailed mechanism of action for CLNH5 have not been publicly disclosed. The drug is positioned as a therapeutic agent within Nascent's oncology portfolio, which also utilizes their proprietary MultiPharm technology platform.
Beyond the preview
Go deeper on CLNH5.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CLNH5.